A detailed history of D. E. Shaw & Co., Inc. transactions in Kura Oncology, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 423,208 shares of KURA stock, worth $3.78 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
423,208
Holding current value
$3.78 Million
% of portfolio
0.01%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.57 - $23.23 $881,592 - $1.1 Million
47,474 Added 12.64%
423,208 $8.27 Million
Q2 2024

Aug 14, 2024

SELL
$17.53 - $22.98 $248,365 - $325,580
-14,168 Reduced 3.63%
375,734 $7.74 Million
Q1 2024

May 15, 2024

BUY
$13.42 - $23.53 $2.47 Million - $4.34 Million
184,282 Added 89.62%
389,902 $8.32 Million
Q4 2023

Feb 14, 2024

SELL
$7.58 - $14.38 $11,218 - $21,282
-1,480 Reduced 0.71%
205,620 $2.96 Million
Q3 2023

Nov 14, 2023

SELL
$8.44 - $11.86 $42,562 - $59,809
-5,043 Reduced 2.38%
207,100 $1.89 Million
Q2 2023

Aug 14, 2023

BUY
$9.62 - $13.99 $404,646 - $588,461
42,063 Added 24.73%
212,143 $2.24 Million
Q1 2023

May 15, 2023

SELL
$10.71 - $14.6 $83,056 - $113,223
-7,755 Reduced 4.36%
170,080 $2.08 Million
Q4 2022

Feb 14, 2023

SELL
$11.23 - $16.9 $1.14 Million - $1.72 Million
-101,624 Reduced 36.36%
177,835 $2.21 Million
Q3 2022

Nov 14, 2022

BUY
$12.01 - $19.45 $2.26 Million - $3.67 Million
188,559 Added 207.44%
279,459 $3.82 Million
Q2 2022

Aug 15, 2022

BUY
$10.71 - $18.33 $289,191 - $494,946
27,002 Added 42.26%
90,900 $1.67 Million
Q1 2022

May 16, 2022

SELL
$11.78 - $16.98 $1.12 Million - $1.61 Million
-95,036 Reduced 59.8%
63,898 $1.03 Million
Q4 2021

Feb 14, 2022

BUY
$12.22 - $19.57 $292,412 - $468,290
23,929 Added 17.72%
158,934 $2.23 Million
Q3 2021

Nov 15, 2021

SELL
$15.42 - $21.72 $2.53 Million - $3.56 Million
-164,005 Reduced 54.85%
135,005 $2.53 Million
Q2 2021

Aug 16, 2021

SELL
$20.85 - $29.88 $1 Million - $1.44 Million
-48,180 Reduced 13.88%
299,010 $6.23 Million
Q1 2021

May 17, 2021

SELL
$24.75 - $39.14 $5.78 Million - $9.14 Million
-233,403 Reduced 40.2%
347,190 $9.82 Million
Q4 2020

Feb 16, 2021

BUY
$29.0 - $41.62 $6.99 Million - $10 Million
240,962 Added 70.95%
580,593 $19 Million
Q3 2020

Nov 16, 2020

BUY
$16.3 - $30.64 $1.24 Million - $2.33 Million
76,174 Added 28.91%
339,631 $10.4 Million
Q2 2020

Aug 14, 2020

BUY
$7.95 - $18.81 $712,455 - $1.69 Million
89,617 Added 51.55%
263,457 $4.29 Million
Q1 2020

May 15, 2020

SELL
$6.45 - $14.04 $576,501 - $1.25 Million
-89,380 Reduced 33.96%
173,840 $1.73 Million
Q4 2019

Feb 14, 2020

BUY
$12.97 - $15.94 $873,166 - $1.07 Million
67,322 Added 34.37%
263,220 $3.62 Million
Q3 2019

Nov 14, 2019

BUY
$14.75 - $20.87 $1.68 Million - $2.38 Million
113,894 Added 138.89%
195,898 $2.97 Million
Q2 2019

Aug 14, 2019

BUY
$14.71 - $19.79 $1.21 Million - $1.62 Million
82,004 New
82,004 $1.62 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $598M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.